 |
This page has not been fully approved by the PsychonautWiki administrators. It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards. |
| Summary sheet: MDPHP |
| MDPHP | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemical Nomenclature | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Common names | MDPHP, Monkey Dust | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Substitutive name | 3',4'-Methylenedioxy-α-pyrrolidinohexiophenone | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Systematic name | 1-(2H-1,3-Benzodioxol-5-yl)-2-(pyrrolidin-1-yl)hexan-1-one | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Class Membership | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Psychoactive class | Stimulant | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chemical class | Cathinone, Pyrrolidine | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Routes of Administration | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Interactions | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
3',4'-Methylenedioxy-α-pyrrolidinohexiophenone (also known as MDPHP and Monkey Dust) is a synthetic stimulant of the cathinone and pyrrolidine classes, and its commonly reported effects include stimulation, disinhibition, increased libido, compulsive redosing, and euphoria when administered orally, insufflated or smoked. MDPHP is thought to act primarily as a norepinephrine-dopamine reuptake inhibitor (NDRI).
MDPHP was first developed in the 1960s by a team at Boehringer Ingelheim[1]
Like other Substituted cathinones, MDPHP is associated with compulsive use and addiction. Its stimulating capabilities are strong and the high is good but it has a tax on your cardiovascular system and the crash is hard as well, recovery can take between 1 to 4 days. Very little data exists about the pharmacological properties, metabolism, and toxicity of MDPHP. Due to its potent psychostimulant effects and unknown toxicity profile, it is highly advised to use harm reduction practices if choosing to use this substance.
It is normally available in its freebase form to be vaped or as HCl to be inhaled. In its freebase form it comes as fine tan powder that gets easily turned into a vapour with a gentle usage of a lighter and a thin foil.
Chemistry
Substituted cathinones are derivatives of the naturally occurring substance cathinone, which is one of the psychoactive principles in khat (Catha edullis). Cathinone is composed of a phenethylamine core with an alkyl group attached to the alpha carbon, and a ketone group attached to the beta carbon.
Pharmacology
MDPHP is thought to act primarily as a potent norepinephrine-dopamine reuptake inhibitor (NDRI). Reduced re-uptake of norepinephrine and dopamine results in higher concentrations of the two catecholamine neurotransmitters in the synaptic cleft, or gap between neurons. The result of this inhibition is an enhanced and prolonged concentration and resulting post-synaptic effect of dopaminergic and noradrenaline signaling at dopamine and norepinephrine receptors on the receiving neuron. Serotonin also plays a role, although to a much lesser degree. This sudden increase in neurotransmitter concentration in the brain is thought to be responsible for the high that MDPHP produces. Mainly possessing re-uptake inhibiting qualities, MDPHP could be considered more like cocaine or methylphenidate than amphetamine in method of action.[2] In contrast, amphetamine acts primarily as an agonist to release dopamine and noradrenaline indirectly via activation of the TAAR1 receptor.
However, despite its structural similarity, the effects of MDPHP bear little resemblance to other methylenedioxy phenylalkylamine derivatives such as 3,4-methylenedioxy-N-methylamphetamine (MDMA), instead producing primarily stimulant effects with only mild entactogenic qualities. It is closely related to the potent stimulant MDPV though with slightly milder effects and lesser compulsive redosing cravings. Although MDPHP was already first synthetized in 1960's,[3] it has been used as an alternative in some countries following the banning of MDPV.
Subjective effects
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects 
-
MDPHP is a strong stimulant generating a broad spectrum of physical effects:
- Stimulation
- Increased libido - This effect is especially notorious with MDPHP.
- Appetite suppression
- Body odor alteration
- Perception of bodily lightness
- Physical euphoria
- Increased blood pressure - The impact on the cardiovascular system is specially hard with MDPHP.
- Increased heart rate
- Vasoconstriction
- Frequent urination
- Muscle cramps
- Teeth grinding
- Temporary erectile dysfunction - Commonly called stimdick.
After effects 
-
The effects which occur during the offset of a stimulant experience generally feel negative and uncomfortable in comparison to the effects which occurred during its peak. This is often referred to as a "comedown" and occurs because of neurotransmitter depletion. Its effects can commonly last between 1 and 4 days and they include:
- Thought disorganization
- Back pain - Mostly due to sustained postures over time.
- Diarrhea
- Physical fatigue - This can last some days and it can be pretty intense depending on the dosage.
- Dream potentiation - It is common to have bad dreams during the next days
Cognitive effects 
-
The general cognitive effects of MDPHP can be described as being similar to those of other typical strong stimulants. At common dosages, the MDPHP high is described as being euphoric and rushy in its effects, causing increased motivation, sociability, sexual desire and concentration. Higher doses of MDPHP, however, can intensify numerous negative effects such as anxiety and disorganized thoughts; at extremely high doses or continued use, delusions and psychosis become likely.
- Increased music appreciation
- Motivation enhancement
- Disinhibition
- Thought disorganization
- Anxiety
- Ego inflation - Similar to the ego inflation of methamphetamine, MDPHP can induce states of egomania at its peak where the user feels capable of everything.
- Focus intensification
- Immersion intensification
- Thought acceleration
- Wakefulness
- Mania
- Paranoia - Present at high doses or after a long period of continuous usage.
- Psychosis - Same as paranoia.
Experience reports
There are currently 0 experience reports which describe the effects of this substance in our experience index.
Additional experience reports can be found here:
Dangerous interactions
Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
- 25x-NBOMe & 25x-NBOH - 25x compounds are highly stimulating and physically straining. Combinations with MDPHP should be strictly avoided due to the risk of excessive stimulation and heart strain. This can result in increased blood pressure, vasoconstriction, panic attacks, thought loops, seizures, and heart failure in extreme cases.
- Alcohol - Combining alcohol with stimulants can be dangerous due to the risk of accidental over-intoxication. Stimulants mask alcohol's depressant effects, which is what most people use to assess their degree of intoxication. Once the stimulant wears off, the depressant effects will be left unopposed, which can result in blackouts and severe respiratory depression. If mixing, the user should strictly limit themselves to only drinking a certain amount of alcohol per hour.
- DXM - Combinations with DXM should be avoided due to its inhibiting effects on serotonin and norepinephrine reuptake. There is an increased risk of panic attacks and hypertensive crisis, or serotonin syndrome with serotonin releasers (MDMA, methylone, mephedrone, etc.). Monitor blood pressure carefully and avoid strenuous physical activity.
- MDMA - Any neurotoxic effects of MDMA are likely to be increased when other stimulants are present. There is also a risk of excessive blood pressure and heart strain (cardiotoxicity).
- MXE - Some reports suggest combinations with MXE may dangerously increase blood pressure and increase the risk of mania and psychosis.
- Dissociatives - Both classes carry a risk of delusions, mania and psychosis, and these risk may be multiplied when combined.
- Stimulants - MDPHP may be dangerous to combine with other stimulants like cocaine as they can increase one's heart rate and blood pressure to dangerous levels.
- Tramadol - Tramadol is known to lower the seizure threshold[4] and combinations with stimulants may further increase this risk.
Legal status
 |
This legality section is a stub. As such, it may contain incomplete or wrong information. You can help by expanding it. |
See also
References
- ↑ Koppe, H., Ludwig, G., Zeile, K. (28 May 1965), Patent DE - Verfahren zur Herstellung von α-Aminoketonen mit heterocyclischer Aminogruppe
- ↑ http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1
- ↑ Herbert, Koeppe; Karl, Zeile; Gerhard, Ludwig (28 May 1965), Patent DE1545591 - Verfahren zur Herstellung von α-Aminoketonen mit heterocyclischer Aminogruppe (in German)
- ↑ Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. eISSN 1937-6995. ISSN 1556-9039. OCLC 163567183.